Ann: Half Year Accounts, page-85

To answer your questions I just picked a handful in order of ASX listing via a google reference & ones I have heard of.
I'm not trying to make b to b comparisons yet in this post, only providing information relating to their 4C's for the purpose to ask what it was that has highlighted these ambiguous negatives that suggest cashflows aren't good enough when it's not in the 4C's?

Yes, I've looked into CAN. They were the first & the most licensed however they are only MM & not a big market here so I assume they will do deals internationally as we all know the Australian market is small. Have you looked into the R&D spent by BOT for a pill? Did you know we have a deal in place with Canntab & Pharmoccan? I'd be looking out for more info & announcements there.

CGB is not growing MM yet however have diversified into complete agricultural to retail chain of businesses that are among the first & best in Australia hemp wise . I suppose the MM deal they could have with bio health or Medcan could secure a future deal with bonnify again once all of the appropriate licensing are in place.....who knows?

Who is CAN selling MM to? If only in Oz then I would say the CGB hemp business will be more profitable no matter how much cash they have on hand.